Skip to content
10-Q

Quarterly Report

Agile Therapeutics, Inc.

0001558370-24-008297

← back to feed
Filed
May 15, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 14, 2024 6.86M sh
Shares Diluted Q1 2024 · Mar 31, 2024 4.63M sh
Shares Diluted Q1 2024 · Mar 31, 2023 912.04K sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$2.48M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$1.6M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $2.62M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $2.56M
Stockholders Equity Q1 2024 · Mar 31, 2024 −$10.32M
Stockholders Equity Q1 2024 · Dec 31, 2023 −$16.32M
Stockholders Equity Q1 2024 · Mar 31, 2023 −$9.43M
Stockholders Equity Q1 2024 · Dec 31, 2022 −$5.55M
Current Liabilities Q1 2024 · Mar 31, 2024 $21.44M
Current Liabilities Q1 2024 · Dec 31, 2023 $20.78M
Total Liabilities Q1 2024 · Mar 31, 2024 $22.93M
Total Liabilities Q1 2024 · Dec 31, 2023 $26.57M
Current Assets Q1 2024 · Mar 31, 2024 $11.99M
Current Assets Q1 2024 · Dec 31, 2023 $9.53M
Total Assets Q1 2024 · Mar 31, 2024 $12.61M
Total Assets Q1 2024 · Dec 31, 2023 $10.26M
Eps Diluted Q1 2024 · Mar 31, 2024 $0.28
Eps Diluted Q1 2024 · Mar 31, 2023 −$5.91
Eps Basic Q1 2024 · Mar 31, 2024 $0.28
Eps Basic Q1 2024 · Mar 31, 2023 −$5.91
Sga Expense Q1 2024 · Mar 31, 2024 $2.62M
Sga Expense Q1 2024 · Mar 31, 2023 $3.09M
Rd Expense Q1 2024 · Mar 31, 2024 $495K
Rd Expense Q1 2024 · Mar 31, 2023 $763K
Net Income Q1 2024 · Mar 31, 2024 $1.28M
Net Income Q1 2024 · Mar 31, 2023 −$5.39M
Operating Income Q1 2024 · Mar 31, 2024 −$2.76M
Operating Income Q1 2024 · Mar 31, 2023 −$6.71M
Gross Profit Q1 2024 · Mar 31, 2024 $4.04M
Gross Profit Q1 2024 · Mar 31, 2023 $1.81M
Cost Of Revenue Q1 2024 · Mar 31, 2024 $1.68M
Cost Of Revenue Q1 2024 · Mar 31, 2023 $2M
Revenue Q1 2024 · Mar 31, 2024 $5.72M
Revenue Q1 2024 · Mar 31, 2023 $3.81M
Short Term Debt Q1 2024 · Dec 31, 2023 $1.52M